Nanjing King-friend Biochemical Pharmaceutical Co Ltd

SHG:603707 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.16 Billion
CN¥15.87 Billion CNY
Market Cap Rank
#9429 Global
#1920 in China
Share Price
CN¥9.82
Change (1 day)
-0.20%
52-Week Range
CN¥9.03 - CN¥14.50
All Time High
CN¥33.62
About

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochlo… Read more

Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: 0.074x

Based on the latest financial reports, Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) has a cash flow conversion efficiency ratio of 0.074x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥502.01 Million) by net assets (CN¥6.75 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Nanjing King-friend Biochemical Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Nanjing King-friend Biochemical Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Nanjing King-friend Biochemical Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nanjing King-friend Biochemical Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Nanjing King-friend Biochemical Pharmaceutical Co Ltd from 2013 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥6.49 Billion CN¥1.50 Billion 0.231x -17.14%
2023-12-31 CN¥5.80 Billion CN¥1.62 Billion 0.279x +189.21%
2022-12-31 CN¥6.17 Billion CN¥595.45 Million 0.097x -23.70%
2021-12-31 CN¥5.40 Billion CN¥683.63 Million 0.127x +183.74%
2020-12-31 CN¥3.74 Billion CN¥-565.85 Million -0.151x +46.05%
2019-12-31 CN¥3.00 Billion CN¥-841.38 Million -0.280x -1187.25%
2018-12-31 CN¥2.42 Billion CN¥62.37 Million 0.026x +122.54%
2017-12-31 CN¥2.05 Billion CN¥-234.59 Million -0.114x +47.60%
2016-12-31 CN¥1.31 Billion CN¥-286.79 Million -0.218x -273.64%
2015-12-31 CN¥1.09 Billion CN¥137.28 Million 0.126x -27.47%
2014-12-31 CN¥1.03 Billion CN¥178.74 Million 0.173x -9.03%
2013-12-31 CN¥1.02 Billion CN¥193.91 Million 0.190x --